Novo Nordisk Investigational Site

Camperdown, New South Wales 2050

0 studies enrolling now · 10 studies all time

What they study most

Asthma, Congenital Bleeding Disorder, Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Haemophilia A, Hepatobiliary Disorders, Metabolism and Nutrition Disorder, Non-alcoholic Steatohepatitis, Obesity

Studies at this site

• Effect of Liraglutide for Weight Management in Paediatric Subjects With Prader-Willi Syndrome — Completed
• A Research Study Looking at How a Factor VIII Medicine Called Turoctocog Alfa Pegol (N8-GP) Works in People With Haemophilia A — Completed
• Investigation of Efficacy and Safety of Three Dose Levels of Subcutaneous Semaglutide Once Daily Versus Placebo in Subjects With Non-alcoholic Steatohepatitis. — Completed
• Evaluation of Safety and Efficacy, Including Pharmacokinetics, of NNC 0129-0000-1003 When Administered for Treatment and Prophylaxis of Bleeding in Subjects With Haemophilia A — Completed
• Evaluating the Haemostatic Effect of NNC 0129-0000-1003 During Surgical Procedures in Subjects With Haemophilia A. — Completed
• Investigation of Safety and Efficacy of Once-daily Semaglutide in Obese Subjects Without Diabetes Mellitus — Completed
• Safety of Inhaled Preprandial Human Insulin in Subjects With Diabetes and Asthma — Stopped early
• Dual Action of Liraglutide and Insulin Degludec in Type 2 Diabetes: A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide, Insulin Degludec and Liraglutide in Subjects With Type 2 Diabetes — Completed
• Trial Investigating Safety, Pharmacokinetics and Pharmacodynamics of Concizumab Administered Subcutaneously to Haemophilia A Subjects — Completed
• Comparison of NN5401 Plus Insulin Aspart With Insulin Detemir Plus Insulin Aspart in Type 1 Diabetes — Completed